Resources
Professional and Patient Websites
American College of Obstetricians and Gynecologists
American Fertility Association
American Society for Reproductive Medicine
American Urological Association
International Council on Infertility Information Dissemination
Medline Plus (National Institutes of Health)
RESOLVE: The National Infertility Association
Society for Assisted Reproductive Technology
These links are provided for information only. The opinions expressed therein do not necessarily reflect those of Watson Pharma, Inc.
Bibliography of Crinone 8% Studies
ACOG Committee on Gynecologic Practice. Committee opinion no. 322: Compounded bioidentical hormones. Obstet Gynecol. 2005;106:1139–1140.
Alper MM, Penzias AS. Crinone® offers excellent implantation rates in patients undergoing IVF. Paper presented at the 16th Annual Meeting of the European Society for Human Reproduction & Embryology; June 2000; Bologna, Italy. Abstract P-059.
Anlar S, Capan Y, Hincal AA. Physico-chemical and bioadhesive properties of polyacrylic acid polymers. Pharmazie. 1993;48:285–287.
Anserini P, Costa M, Remorgida V, Sarli R, Guglielminetti E, Ragni N. Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective, randomized study [in Italian]. Minerva Ginecol. 2001;53:297–301.
Berger B, Phillips JA. A retrospective analysis of pregnancy outcomes in recipients of anonymously donated oocytes at a large ART center. Fertil Steril. 2008;89:S11–S12.
Berger BM, Phillips JA. A retrospective analysis of pregnancy outcomes in recipients of frozen/thawed embryos (FET) from donated oocytes at a large assisted reproductive technology (ART) center. Fertil Steril. 2008;90(suppl 1):S459. Abstract A-260.
Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–1079.
Chantilis SJ, Zeitoun KM, Patel SI, et al. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829.
Cicinelli E, de Ziegler D, Bulletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–406.
Coutifaris C, Patrizio P, Schafer D, Bunso S, Bucci J, Barnhart K. Is the use of Crinone for support of the luteal phase detrimental to pregnancy outcome after transfer of non-cryopreserved embryos in good prognosis patients? A preliminary report. Fertil Steril. 2000;74(suppl 1):S205. Abstract P-350.
Doody K, Shamma N, Paulson R, Bayer S, Blake E, Yankov V. Endometrin® for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur® and Bravelle®. Fertil Steril. 2007;87(suppl 2):S24. Abstract P-34.
Elkind-Hirsch KE, Phillips K, Bello SM, McNichol M, de Ziegler D. Sequential hormonal supplementation with vaginal estradiol and progesterone gel corrects the effect of clomiphene on the endometrium in oligo-ovulatory women. Hum Reprod. 2002;17:295–298.
Elkind-Hirsch KE, Darensbourg C, Creasy G, Gipe D. Conception rates in clomiphene citrate cycles with and without hormone supplementation: a pilot study. Curr Med Res Opin. 2005;21:1035–1040.
Erdem A, Erdem M, Atmaca S, Guler I. Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study. Fertil Steril. In press.
Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reprod BioMed Online. 2007;14:155–158. Available at: rbmonline.com/Article/2551.
Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101.
Kleinstein J. Efficacy and tolerability of vaginal progesterone capsules (Utrogest™ 200) compared with progesterone gel (Crinone™ 8%) for luteal phase support during assisted reproduction. Fertil Steril. 2005;83:1641–1649.
Levine H. Luteal support from the vaginal progesterone (P) gel Crinone 8%: preliminary results of multicenter trial show higher pregnancy rates than historical controls. J Soc Gynecol Investig. 2000;7(suppl):203A. Abstract 571.
Ludwig M, Schwartz P, Babahan B, et al. Luteal phase support using either Crinone® 8% or Utrogest®: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002;103:48–52.
Park H, Robinson JR. Physico-chemical properties of water insoluble polymers important to mucin/epithelial adhesion. J Control Release. 1985;2:47–57.
Saucedo LLE, Galache VP, Hernández AS, Santos HR, Arenas ML, Patrizio P. Randomized trial of three different forms of progesterone supplementation in ART: preliminary results. Fertil Steril. 2000;74(suppl 1):S150. Abstract P-175.
Saucedo LLE, Batiza V, Arenas L, et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration. Paper presented at the 19th Annual Meeting of the European Society for Human Reproduction & Embryology; July 2003; Madrid, Spain. Abstract P-383.
Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–1288.
Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. Fertil Steril. 2007;87:83–87.
Warren MP, Biller BMK, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol. 1999;180:42–48.
Williams SC, Donahue J, Muasher SJ. Vaginal progesterone therapy during programmed cycles for frozen embryo transfer: an analysis of serum progesterone levels and pregnancy rates. Fertil Steril. 2000;74(suppl 1):S209. Abstract P-363.
Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2008;89:485–487.
Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer (IVF/ET) in women under age 40: a prospective randomized trial. Fertil Steril. 2006;86(suppl):S6. Abstract O-13.
Important Safety Information
The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No adequate evidence is available to show that progesterone and progestins are effective in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a history of psychic depression, and those with diabetes.